Literature DB >> 12145726

Association between antimicrobial resistance among pneumococcal isolates and burden of invasive pneumococcal disease in the community.

Julia Y Morita1, Elizabeth R Zell, Richard Danila, Monica M Farley, James Hadler, Lee H Harrison, Lewis Lefkowitz, Arthur Reingold, Benjamin A Kupronis, Anne Schuchat, Cynthia G Whitney.   

Abstract

Treatment of infections with drug-resistant strains of Streptococcus pneumoniae (pneumococcus) may fail; whether drug resistance is associated with an increase in the number of serious infections in the community is unknown. We evaluated the relationship between the proportion of antimicrobial-resistant S. pneumoniae isolates and the number of cases of invasive pneumococcal disease. Linear regression models included 1996 county-level data from 38 counties participating in the US Centers for Disease Control and Prevention's Active Bacterial Core Surveillance. Separate models evaluated hospitalized children aged <5 years, nonhospitalized children aged <5 years, adults aged 18-64 years, and adults aged >64 years. The proportion of isolates resistant to > or =3 drug classes was associated with invasive disease in both hospitalized (P=.06) and nonhospitalized (P=.001) children. The proportion of multidrug-resistant pneumococcal isolates did not predict invasive cases among adults. The increasing prevalence of multidrug-resistant pneumococci among children may be leading to an increase in invasive disease.

Entities:  

Mesh:

Year:  2002        PMID: 12145726     DOI: 10.1086/341897

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia.

Authors:  Mark I Neuman; Meera Kelley; Marvin B Harper; Thomas M File; Carlos A Camargo
Journal:  J Emerg Med       Date:  2007-03-30       Impact factor: 1.484

2.  Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.

Authors:  Rajesh Singh; Shailesh Singh; Praveen K Sharma; Udai P Singh; David E Briles; Susan K Hollingshead; James W Lillard
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

3.  High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).

Authors:  Jae-Hoon Song; Sook-In Jung; Kwan Soo Ko; Na Young Kim; Jun Seong Son; Hyun-Ha Chang; Hyun Kyun Ki; Won Sup Oh; Ji Yoeun Suh; Kyong Ran Peck; Nam Yong Lee; Yonghong Yang; Quan Lu; Anan Chongthaleong; Cheng-Hsun Chiu; M K Lalitha; Jennifer Perera; Ti Teow Yee; Gamini Kumarasinghe; Farida Jamal; Adeeba Kamarulzaman; Navaratnam Parasakthi; Pham Hung Van; Celia Carlos; Thomas So; Tak Keung Ng; Atef Shibl
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

4.  Burden of Serious Bacterial Infections and Multidrug-Resistant Organisms in an Adult Population of Nepal: A Comparative Analysis of Minimally Invasive Tissue Sampling Informed Mortality Surveillance of Community and Hospital Deaths.

Authors:  Suraj Bhattarai; Binita Koirala Sharma; Nuwadatta Subedi; Sunita Ranabhat; Madan Prasad Baral
Journal:  Clin Infect Dis       Date:  2021-12-15       Impact factor: 9.079

5.  Genome evolution driven by host adaptations results in a more virulent and antimicrobial-resistant Streptococcus pneumoniae serotype 14.

Authors:  Feng Ding; Petrus Tang; Mei-Hua Hsu; Peng Cui; Songnian Hu; Jun Yu; Cheng-Hsun Chiu
Journal:  BMC Genomics       Date:  2009-04-13       Impact factor: 3.969

Review 6.  Infectious diseases and vaccine sciences: strategic directions.

Authors:  Stephen P Luby; W Abdullah Brooks; K Zaman; Shahed Hossain; Tahmeed Ahmed
Journal:  J Health Popul Nutr       Date:  2008-09       Impact factor: 2.000

7.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.